

Subject Index

Adjuvant treatment, 51 (24), 107 (204), 127 (275)
 Chemotherapy, 148 (347), 149 (348)
 Early breast cancer, 95 (175), 151 (354), 152 (358)
 Elderly/geriatric patients, 154 (364)
 Elderly patients, 109 (212)
 Metastatic/advanced breast cancer, 48 (15), 115 (231), 151 (355), 157 (374)
 Prognosis estimation, 153 (360), 156 (371), 157 (373)

Anastrozole – see under Aromatase inhibitors

Angiogenesis, 126 (271, 272), 144 (329)
 Prognostic factors, 126 (271, 272), 144 (329)
 Treatment target, 46 (6)

Apoptosis – see Tumour biology

Arimidex – see Aromatase inhibitors, anastrozole

Aromatase inhibitors, 158 (375)
 Anastrozole, 81 (132), 94 (172), 96 (179), 105 (199), 165 (401), 167 (409)
 Exemestane, 96 (179), 105 (199), 152 (358), 155 (368), 167 (407, 409)
 Letrozole, 81 (132), 96 (179), 109 (209), 129 (282), 142 (324), 143 (326), 154 (362), 163 (395)

Autologous transplantation, 24 (E10)

Axilla, 35 (E16)

Axillary lymph nodes, 76 (112), 97 (181)
 Micrometastasis, 80 (126), 115 (233)
 Prognostic factor, 50 (21), 72 (98), 73 (101, 102), 76 (111), 77 (117), 78 (121), 99 (189), 114 (227), 115 (232), 128 (279)
 Ultrasonography, 60 (55)

Bcl-2, 82 (133), 121 (254)

Bevacizumab, 163 (395)

Biopsy, 35 (E16), 38 (E17)

Biopsy techniques, 58 (47), 61 (56), 82 (136), 83 (137), 124 (262), 148 (345)
 Core needle, 58 (47), 61 (56), 82 (136), 83 (137), 124 (262), 148 (345)
 Photosensitizer-assisted, 81 (130)
 Radioguided, 78 (118)
 Surgical excision, 61 (56), 123 (260)

Ultrasound-guided, 148 (345)

Bisphosphonates, 20 (E8)
 Adjuvant treatment, 136 (302)
 Clodronate, 150 (352)
 Ibandronate, 164 (398), 166 (404)
 Pamidronate, 163 (392)
 Persistence/compliance, 166 (403)
 Zoledronate, 46 (5), 48 (12, 13), 164 (398), 166 (404)

Bone metastasis (see also Metastatic/advanced breast cancer), 20 (E8), 163 (393)
 Bisphosphonates, 46 (5), 136 (302), 150 (352), 163 (392), 164 (398), 166 (403, 404)

Brain metastasis (see also Metastatic/advanced breast cancer), 163 (394), 164 (396), 165 (399, 402), 171 (422)

Breast carcinoma in situ (BCIS), 65 (71)

Breast conserving surgery, 92 (165), 127 (276)
 Aesthetic outcome, 80 (129)
 Breast reconstruction, 71 (94, 95), 72 (96), 75 (110), 118 (244), 119 (245, 246)
 Chemoradiotherapy, 51 (24)
 Early breast cancer, 50 (21), 51 (23, 24), 74 (105), 107 (205)
 Elderly/geriatric patients, 110 (214)
 Local recurrence, 51 (22), 52 (25), 64 (66), 72 (99), 128 (278), 158 (378), 160 (383)
 Radiotherapy, 50 (21), 51 (23), 74 (105), 83 (138), 98 (183), 99 (186), 101 (195, 196), 102 (197), 108 (207), 118 (244)
 Residual tumour, 73 (103)
 Surgical practice, 119 (245, 246)

Breast neoplasms, 33 (E15), 35 (E16), 38 (E17), 41 (E18)

Breast Units, 55 (37), 67 (79), 75 (107), 76 (114), 77 (116), 85 (145), 87 (151), 92 (166), 181 (446)

c-erbB-2 – see Her-2/neu

Calcinosis, 38 (E17)

Carcinoma intraductal, 38 (E17)

Chemotherapy/adjuvant chemotherapy, 51 (24), 88 (153), 162 (389), 167 (406), 173 (430)
 Anthracyclines, 46 (6), 169 (416), 178 (434, 435)
 Antimetabolites, 148 (347), 156 (370), 158 (376), 167 (408), 168 (410, 413), 169 (416)

Chemotherapy/adjuvant chemotherapy (*cont'd*)

Bisphosphonates, 46 (5), 48 (12, 13), 136 (302), 150 (352), 163 (392), 164 (398), 166 (403, 404)
 Chemosensitivity prediction, 111 (218), 116 (235), 117 (237)
 CMF, 170 (419)
 Doxorubicin, 108 (208), 141 (320)
 Elderly/geriatric patients, 154 (364)
 Epirubicin, 153 (361), 156 (369, 370), 158 (376), 165 (400)
 High dose, 24 (E10)
 High risk patients, 154 (363)
 Neoadjuvant chemotherapy, 73 (101), 75 (108), 117 (238, 239), 155 (365), 157 (372, 374), 159 (379, 380)
 Peri-operative chemotherapy, 149 (349), 155 (367), 158 (376)
 Predictive factors, 155 (366)
 Prognostic factors, 45 (4)
 Taxanes, 47 (7), 108 (208), 148 (347), 151 (356), 156 (369, 370), 157 (372, 374), 158 (376), 161 (388), 168 (410, 411, 413), 169 (414, 416, 417), 171 (424), 172 (426), 178 (434, 435)
 Toxicity and side effects, 48 (11, 12, 13), 88 (154), 90 (160), 94 (173, 174), 95 (176), 151 (356)
 Vinca alkaloids, 148 (347), 167 (408), 168 (411, 412, 413), 169 (417)

Classification, 26 (E11)

Clinical practice/guidelines/attitudes, 64 (68), 65 (73), 75 (107), 83 (139), 85 (146), 89 (156), 90 (160), 91 (163), 92 (166, 167), 93 (169), 94 (171), 100 (192)
 Breast cancer management, 76 (114), 77 (116), 178 (438), 179 (439, 440)
 Data management, 85 (144)
 Education, 84 (140, 141, 142, 143), 86 (147, 149), 87 (150), 120 (249), 177 (431), 180 (445), 181 (447)
 Guidelines, 68 (84), 87 (151), 110 (213), 179 (439, 440)
 Quality control, 63 (65), 64 (67), 67 (79), 68 (81), 74 (104), 90 (158, 161), 91 (162), 97 (180)
 Status reports, 68 (82), 70 (88), 71 (92), 74 (106)

Clinical studies, 38 (E17), 59 (50), 62 (59), 64 (66), 65 (71), 96 (177), 123 (259), 127 (276), 129 (281, 282), 147 (342, 343, 344), 148 (345, 346), 155 (366), 167 (406, 409), 168 (410, 412, 413), 169 (414, 416, 417), 170 (418)

Clinical trials, 117 (240)

Overviews, 119 (248)
 Reports, 47 (10, 7), 48 (11), 70 (91), 77 (115), 87 (152), 96 (178), 105 (199), 107 (204), 109 (209), 111 (219), 112 (221), 113 (226), 114 (230), 116 (234), 118 (243), 126 (270), 135 (299, 301), 143 (326), 149 (349, 350), 150 (351, 352, 353), 151 (355), 153 (361), 154 (362, 363), 155 (365, 367, 368), 156 (369, 370), 158 (375), 161 (388), 165 (400), 166 (404), 167 (408), 168 (411), 173 (429), 178 (436)
 Study design, 49 (17, 18), 50 (19), 109 (211), 112 (222), 179 (441), 180 (442)

Clodronate – see Bisphosphonates**Complementary and alternative treatment**, 89 (156)**Complementary medicine**, 96 (178)**Computers/simulation**, 61 (57), 85 (145), 153 (360)

Cost control, 15 (E6), 55 (37), 56 (41), 93 (168), 147 (343), 149 (348), 151 (354), 152 (358)

Cost-effectiveness, 15 (E6)**Cytology**, 35 (E16), 38 (E17)**Diagnosis**, 4 (E2), 28 (E12), 29 (E13), 59 (51), 177 (432)

Biopsy techniques, 58 (47), 78 (118)
 Computer-aided, 61 (57)
 Core needle, 31 (E14)
 Cost-effectiveness, 49 (16)
 Delayed diagnosis, 64 (67)
 Differential, 38 (E17)
 Familial cancer/genetic testing, 59 (49), 142 (323)
 Lymph node involvement, 60 (53)
 Management, 64 (68)
 Recurrent disease, 138 (310), 139 (315)

Diagnostic imaging, 101 (194)

CT, 101 (194)
 Digital mammography, 57 (42)
 FDG-PET, 62 (60), 159 (380)
 Magnetic resonance, 59 (50)
 Mammography, 35 (E16), 38 (E17), 54 (34), 55 (35, 36), 57 (42, 43), 58 (46), 59 (49), 61 (56), 63 (62), 77 (115), 82 (134), 132 (292), 147 (343), 159 (379)
 Micro-endoscopy, 59 (51)
 MRI, 35 (E16), 38 (E17), 48 (14, 15), 58 (48), 59 (49), 60 (54), 61 (57), 62 (58, 59), 63 (64), 64 (66, 69), 105 (200), 106 (201), 147 (342), 159 (379), 171 (422)
 Overview, 35 (E16), 38 (E17)
 PET-CT, 65 (70)
 Ultrasonography, 28 (E12), 31 (E14), 33 (E15), 35 (E16), 38 (E17), 41 (E18), 60 (52, 55), 61 (56), 63 (63, 64), 80 (127), 148 (346), 159 (379)

Disease entities, 2 (E1)

Docetaxel, 108 (208), 148 (347), 151 (356), 156 (370), 157 (372, 374), 158 (376), 161 (388), 168 (410, 411, 413), 171 (424)

Drug resistance, 132 (290), 138 (309, 311), 144 (332), 145 (337), 158 (377), 172 (427)

Ductal carcinoma in situ (DCIS), 64 (69), 79 (124), 82 (135), 83 (137), 121 (254), 145 (333)

Histopathology/classification, 64 (69), 79 (124), 82 (135), 83 (137), 121 (254), 145 (333)
 Prognostic factors, 132 (289, 292), 137 (307)
 Screening, 82 (134), 99 (187)
 Treatment response, 22 (E9), 81 (132), 83 (138), 108 (207)

Early breast cancer, 88 (153), 89 (157), 91 (164)

Adjuvant chemotherapy, 88 (154), 94 (172), 108 (208), 158 (376)
 Breast conserving surgery, 50 (21), 51 (23), 74 (105), 75 (110), 102 (197), 107 (205)
 Endocrine therapy, 151 (354), 152 (357)
 Prognostic factors, 50 (20), 65 (70), 116 (234), 121 (252)
 Radiotherapy, 50 (21), 51 (23), 74 (105), 87 (152), 102 (197)

Elderly/geriatric patient care, 70 (89, 90), 72 (98), 96 (177), 109 (211, 212), 110 (213, 214), 154 (364), 171 (424)

Endocrine therapy/adjuvant endocrine therapy, 111 (217), 131 (288), 135 (301), 142 (324), 146 (339), 171 (421, 423), 177 (433)

- EORTC trials**, 78 (121), 97 (180), 100 (191), 108 (207), 111 (218), 114 (230), 117 (237), 128 (278), 149 (349), 170 (419)
- Epidemiological studies**, 56 (40, 41), 60 (53), 65 (72), 66 (75, 76, 77), 67 (78, 80), 68 (82, 83), 69 (85, 87), 70 (88, 89, 90, 91), 73 (101), 77 (117), 79 (122), 82 (134), 83 (138), 85 (146), 87 (152), 96 (178), 98 (185), 109 (210, 211), 110 (214), 111 (219), 112 (220), 113 (225, 226), 115 (232), 118 (242), 122 (256), 123 (258, 260, 261), 126 (270), 127 (274, 275), 128 (277), 129 (280), 133 (295, 296), 136 (304), 150 (353), 151 (355), 154 (362, 363), 155 (368), 157 (373), 160 (384), 161 (387), 162 (389, 390), 173 (429), 180 (443, 444)
- Estrogen and progesterone receptors**, 70 (89), 96 (179), 111 (217, 219), 124 (264), 125 (267), 126 (273), 130 (284, 285), 131 (286), 135 (299), 136 (303, 305), 137 (306), 140 (316), 145 (334, 337), 146 (340), 149 (350), 150 (353), 163 (395), 170 (418), 177 (433)
- Exemestane – see under Aromatase inhibitors**
- Familial cancer/genetic testing**, 63 (62), 127 (274), 140 (318)
 BRCA1/BRCA2 carriers, 63 (62), 127 (274), 140 (318)
 BRCA1/BRCA2 prevalence/screening, 54 (30), 67 (78), 71 (92), 74 (106)
 Diagnosis, 49 (16), 106 (202)
 Genetic counselling, 54 (31, 32), 91 (163)
 Prophylactic mastectomy, 69 (86, 87)
 Psychological morbidity, 88 (155)
 Risk estimation, 133 (294)
 Surveillance, 55 (37), 58 (48), 59 (49), 88 (155), 93 (170)
- Fracture**, 20 (E8)
- Her-2/neu**, 68 (83), 108 (208), 137 (307), 145 (333), 146 (340), 158 (377), 161 (388), 163 (394)
 FISH, 113 (225)
 Her-2-positive cancers, 168 (412), 169 (417), 170 (419), 173 (429)
 Predictive/prognostic factor, 49 (17), 67 (80), 110 (216), 112 (221), 132 (290), 155 (365), 164 (396, 397), 165 (400, 402)
- Herceptin – see Trastuzumab**
- Histology**, 35 (E16), 38 (E17)
- Hormone replacement therapy**, 45 (4), 46 (6), 57 (44), 117 (240), 160 (385), 167 (406)
 Complementary medicine, 118 (243), 152 (359)
 Fulvestrant, 150 (353), 162 (391), 170 (418), 171 (423)
 Goserelin, 167 (409)
 Risk factor, 66 (76), 117 (241), 118 (242)
 Tamoxifen, 96 (179), 142 (324), 150 (353)
 Tibolone, 96 (178), 126 (270)
- Hypercalcaemia**, 20 (E8)
- Individualized medicine**, 2 (E1)
- Letrozole – see under Aromatase inhibitors**
- Lobular carcinoma in situ (LCIS)**, 22 (E9)
 Local recurrence, 22 (E9)
- Local recurrence**, 13 (E5), 160 (382)
- Loco-regional control**, 10 (E4)
- Lymph node excision**, 35 (E16)
- Lymphoedema**, 79 (123)
- Male breast cancer**, 124 (264)
- Metastatic/advanced breast cancer**, 17 (E7), 45 (4), 46 (6), 47 (7), 60 (55), 80 (126, 128), 115 (232), 116 (235, 236), 123 (259), 124 (265), 132 (290), 139 (312, 314), 163 (393), 166 (405), 170 (420), 178 (438), 179 (439, 440)
 Adjuvant chemoradiotherapy, 115 (231), 151 (355)
 Adjuvant chemotherapy, 98 (185), 117 (237), 157 (372), 159 (379, 380), 162 (390), 167 (406)
 Adjuvant hormone/radiotherapy, 152 (359)
 Anthracyclines, 178 (434, 435)
 Antimetabolites, 162 (389), 168 (410, 413), 169 (416)
 Aromatase inhibitors, 163 (395), 165 (401), 167 (407, 409)
 Bisphosphonates, 163 (392)
 Bone, 46 (5)
 Bone marrow metastasis, 109 (210)
 Brain metastases (*see also* Brain metastasis), 165 (402)
 Chemotherapy, 167 (408), 170 (419)
 Counselling, 94 (171)
 Docetaxel, 161 (388), 168 (410, 411, 413)
 Endocrine therapy, 162 (391), 169 (414), 170 (418), 171 (423)
 Hormonal therapy, 167 (406)
 Models, 169 (415)
 Prognostic factors, 134 (298), 161 (387)
 PS-341, 173 (429)
 SU11248, 172 (425)
 Taxanes, 169 (414, 417), 171 (424), 178 (434, 435)
 Trastuzumab, 163 (394), 165 (400), 168 (412), 169 (416, 417), 170 (419), 173 (429)
 Vinca alkaloids, 168 (411, 412, 413), 169 (417)
- Molecular profiles**, 2 (E1)
- Neoplasm staging**, 35 (E16), 38 (E17)
- New entities**, 26 (E11)
- Nursing**, 52 (26), 53 (27, 28, 29), 93 (168, 169, 170)
- Osteoclast**, 20 (E8)
- Osteolysis**, 20 (E8)
- Over-diagnosis**, 6 (E3), 26 (E11)
- Paclitaxel**, 47 (7), 156 (369), 169 (414), 172 (426)
- Pain**, 20 (E8)
- Pathology**, 26 (E11), 38 (E17), 59 (51), 69 (86), 121 (254), 122 (256, 257), 123 (258, 259, 260, 261), 124 (263, 264, 265), 145 (333)
 Techniques, 122 (255), 124 (262, 266)
- Predictive factors**, 26 (E11), 60 (54), 65 (72), 93 (170), 122 (256)
 Biomarkers, 141 (321)
 BRCA1/BRCA2 status, 128 (277), 136 (304)
 Familial cancer, 133 (294)
 Lipophilin B, 144 (331)

Predictive factors (*cont'd*)

- Response to therapy, 111 (217, 218), 112 (223), 131 (268), 140 (317)
- Sentinel lymph node, 77 (117)

Prevention, 45 (2)

- Chemoprevention, 47 (10, 8, 9), 48 (11), 105 (199)
- Prophylactic surgery, 69 (86, 87), 136 (304)

Prioritisation, 15 (E6)**Prognostic factors**, 26 (E11), 49 (18), 66 (77), 68 (83), 106

- (203), 112 (220), 127 (274), 129 (280), 132 (292), 133 (294, 295), 135 (299), 141 (319), 144 (330), 145 (335), 153 (360)
- Activated c-Src, 137 (307)
- Age, 121 (252), 128 (276), 130 (283), 134 (298), 140 (318)
- Amenorrhea, 152 (357)
- ATBF1-A expression, 145 (336)
- Axillary lymph node status, 128 (279)
- Basal phenotype, 113 (224)
- Biomarkers, 141 (321)
- Bone marrow metastases, 109 (210)
- BRCA1/BRCA2 status, 127 (276), 128 (277)
- Circulating endothelial cells, 144 (329)
- Cyclin E, 130 (284)
- Disseminated epithelial cells, 139 (315)
- ErbB, 139 (313)
- Estrogen/progesterone receptor, 111 (219)
- Estrogen receptor, 130 (285), 137 (306), 142 (322)
- Gene expression profiling, 50 (20), 127 (275), 129 (282), 131 (287), 133 (293), 135 (300), 136 (302), 139 (312)
- Her-2/neu, 110 (216)
- HIF-1 α , 132 (291)
- Histone modifications, 134 (297)
- IGF-1, 143 (328)
- Inflammation, 125 (268)
- Ki67, 135 (301)
- Mib1, 123 (261)
- Regulatory T-cell number, 131 (286)
- Screen detection, 58 (45)
- Steroid receptor status, 156 (371)
- Tumour characteristics, 129 (281), 132 (289)

Psycho-oncology, 83 (139), 92 (165)

- Counselling, 54 (31, 32)
- Education, 54 (30), 84 (140, 141, 143), 86 (147, 149), 87 (150), 90 (159), 121 (253), 177 (431), 180 (445)
- Family life, 87 (152)
- Follow-up, 52 (26), 53 (27, 28), 90 (161), 93 (168)
- Patient/family communications, 53 (29), 84 (142), 92 (166), 94 (171), 120 (249)
- Patient survey, 53 (28), 90 (158), 91 (162), 93 (169), 119 (247), 121 (253), 159 (381)
- Psychological morbidity, 88 (155)
- Psychosocial support, 89 (156), 92 (167)
- Public awareness, 86 (148), 179 (441), 180 (442)
- Quality of life, 86 (153, 154), 89 (157), 90 (160), 162 (369), 165 (401)

Radiotherapy, 10 (E4), 20 (E8)

- Axillary treatment, 97 (181)
- Breast conserving surgery, 50 (21), 51 (22, 24), 74 (105), 83 (138), 99 (186), 108 (207), 118 (244)
- Chemoradiotherapy, 113 (226)
- Early breast cancer, 50 (21), 51 (23)
- Intensity-modulated radiotherapy, 97 (182)

- Intra-operative radiotherapy, 52 (25), 101 (196)
- Local/regional treatment, 96 (177), 108 (206)
- Locally advanced disease, 116 (236)
- Neoadjuvant radiotherapy, 152 (359)
- Palliative radiotherapy, 163 (392)
- Post-operative radiotherapy, 72 (97), 98 (183, 185), 99 (187, 188, 189), 100 (192), 112 (221), 133 (295)
- Quality assurance, 97 (180)
- Radioresistance, 101 (193)
- Re-irradiation, 160 (385)
- Techniques, 100 (190), 101 (194, 195, 196)

Rare tumours, 69 (85)

- Axillary lymphadenopathy without clinically palpable primary, 69 (85)
- Phyllodes tumor, 129 (281)
- Primary breast sarcoma, 129 (281)

Research and Management issues, 45 (1, 2), 46 (6), 47 (9),

- 49 (16, 17, 18), 50 (19, 20), 62 (61), 105 (198), 110 (215), 171 (421), 180 (443, 444), 181 (446, 447)

Screening, 4 (E2), 6 (E3), 29 (E13)

- Cost-effectiveness, 49 (16)
- Efficiency, 56 (38), 58 (45), 66 (74)
- Frequency, 54 (33)
- Mammography, 54 (34), 57 (42, 43), 59 (49)
- MRI, 58 (48), 59 (49), 105 (200), 106 (201)
- Public awareness, 86 (148)
- Quality assurance, 63 (65)
- Quality control, 58 (46)
- Recommendations, 74 (104)
- Screening programmes, 55 (35, 36), 56 (40, 41), 57 (42, 43, 44), 74 (104)
- Surveillance, 55 (37)

Sensitivity and specificity, 35 (E16), 38 (E17)**Sentinel lymph node**, 17 (E7), 35 (E16), 79 (124), 80 (129), 114 (228)

- After neoadjuvant chemotherapy, 75 (108)
- After previous biopsy, 78 (120), 83 (137)
- Effectivity, 79 (125)
- Metastasis assessment, 66 (75), 79 (122), 80 (126, 128), 115 (233), 124 (266)
- Patient selection, 80 (127)
- Risk factor, 79 (123), 114 (229)
- Techniques, 78 (118), 81 (130, 131), 115 (232)
- Validation, 73 (101), 76 (111), 77 (117), 78 (119, 121), 82 (135), 114 (227, 230)

Side effects of treatment, 94 (172, 173, 174), 95 (175, 176), 151 (356), 161 (386)**Signal transduction pathways** – *see* Tumour biology**Skeleton**, 20 (E8)**Supportive therapy**, 71 (93), 147 (344)**Surgery**, 35 (E16), 38 (E17), 56 (39), 73 (100), 75 (109), 96 (178), 132 (292), 147 (344)

- Ambulatory surgery, 75 (107)
- Appropriateness, 56 (38)
- Breast conserving surgery, 72 (99), 73 (103), 83 (138)
- Breast reconstruction, 71 (94, 95), 72 (96)
- Complications, 80 (126)

Surgery (*cont'd*)

Follow-up, 52 (26), 86 (147), 99 (188)
 Mastectomy, 63 (64), 71 (93), 98 (184), 161 (386)
 Overview, 76 (114)
 Psychological aspects, 89 (157), 92 (165)
 Quality assurance, 74 (104)
 Techniques, 73 (102), 76 (111, 112, 113), 77 (115), 116 (234)

Surgical margins – see Surgery**Tamoxifen therapy**, 142 (324), 145 (337)

Adjuvant tamoxifen, 94 (172), 118 (243), 127 (275), 152 (358)
 Aromatase inhibitors, 143 (326), 158 (375), 167 (409)
 Chemoprevention, 47 (10, 8, 9), 48 (11), 105 (199)
 Compliance/persistence, 96 (179)
 Pre-menopausal patients, 131 (268)
 Tamoxifen resistance, 138 (311), 144 (332), 158 (377), 172 (427)

Targeted treatment, 172 (427)

c-Src, 173 (428)
 Curcumin, 172 (426)
 Lectins, 146 (338)
 mTOR inhibition, 142 (325)
 Overview, 112 (222, 223), 173 (430)
 p21, 141 (320)
 SU11248, 172 (425)

Taxanes – see Docetaxel and Paclitaxel

Trastuzumab, 108 (208), 157 (374), 161 (388), 163 (394), 165 (400), 168 (412), 169 (416), 173 (429), 178 (436)
 Drug resistance, 132 (290)

Metastatic disease, 113 (225)

Toxicity and side effects, 113 (226), 170 (419)

Treatment, 13 (E5), 17 (E7)**Tumour biology**, 126 (271, 272)

Angiogenesis, 126 (271, 272)
 COX-2 expression, 145 (333)
 Drug resistance, 138 (309)
 Estrogen receptor, 125 (267), 126 (270, 273)
 Galectin-1 expression, 146 (338)
 Gene expression, 67 (80), 136 (302), 143 (327)
 IGF-1 expression, 143 (328), 147 (341)
 Inflammatory phenotype, 125 (268, 269)
 P53, 141 (320)
 Radioresistance, 101 (193)
 Signaling pathways, 138 (308)
 Xenograft models, 45 (3)

Vascularisation, 41 (E18)**Young patients**, 119 (248), 123 (258)

Communication, 120 (249), 121 (253)
 Pregnancy, 120 (250, 251)
 Prognostic factors, 121 (252), 128 (278), 130 (283, 285), 134 (298), 160 (364)

Zoledronate – see Bisphosphonates